The Brookings Health System doctor will cover diabetes, weight loss and where GLP-1 drugs are headed, airing live at 7 PM Central.
Recap by typeshit. Post by Facebook on Facebook.
The clinic says the choice should weigh long term outcomes and overall health, not just pounds lost, and that no single treatment fits everyone.
15:25
Doctor Alex says Ozempic works but comes with a catch, and walks through what he thinks people misunderstand about GLP-1 drugs.
Lilly reports on Oct. 29, and Zacks expects investors to focus on Foundayo after the oral GLP-1 brought in $98 million in its first full quarter on sale.
Kalkine Media ties the attention on Lilly to orforglipron's progress, arguing a pill could scale cheaper than injectables and ease supply limits.
The telehealth company's press release says the price stays flat as doses rise, billed $375 per quarter. Compounded versions are not FDA approved, the release notes.
Neither has a controlled human trial for sports injuries. An FDA advisory panel voted 8 to 6 in July 2026 to back compounding BPC-157, but the FDA has not decided.
Loading…